modified immune cells

Modified immune cells (MIC), also known as MIC-Lx, is an investigational personalized cell therapy developed by TolerogenixX to induce antigen-specific immune tolerance in organ transplantation and autoimmune diseases. The therapy is manufactured by collecting peripheral blood mononuclear cells (PBMCs) from a donor (or the patient, in the case of autoimmune diseases) via leukapheresis, and modifying them ex vivo by treatment with the cytostatic agent mitomycin C (MMC). This treatment alters the cell surface characteristics, downregulating co-stimulatory signals and upregulating inhibitory signals, thereby rendering the cells tolerogenic. When administered intravenously prior to transplantation, MICs induce donor-specific immune tolerance in the recipient, promoting the generation of regulatory B cells (Bregs) and regulatory T cells (Tregs) while undergoing programmed apoptosis. This approach aims to protect the transplant graft and reduce or eliminate the need for lifelong systemic immunosuppressive therapy.

Other names

MICMIC therapyModified Immune Cells